“High Cost Drugs”

24 result(s)
Pharmacy Innovation
Point-of-sale rebates and zero-dollar copay plans can help alleviate the impact of high drug costs for members in HDHPs during the deductible phase. More
Commentary
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature
Cost Management
CVS Health is launching real-time benefits which, for the first time ever, will offer members and their health care providers transparent, real-time access to member-specific... More
Briefing
Pharmacist filling prescriptions in a timely manner
Cost Management
Paying-for-performance is where health care is headed. CVS Health’s new performance network will deliver unit cost savings, as well as improved clinical outcomes to help lower... More
Briefing
The MS Care Challenge
Care Management
MS is a chronic, progressive and unpredictable condition and each patient’s needs are unique. Caring for MS patients requires a holistic, tailored approach. More
Briefing
Expensive Pill
Cost Management
Value-based management can only deliver on their promise of incremental cost-savings if the right guardrails are in place to ensure appropriate utilization and management. More
Briefing
24% Drop in Client Cost for Epinephrine Injectors
Cost Management
Despite triple digit price hikes, PBM trend management solutions helped lower the costs of epinephrine injectors 24% for clients for drugs covered under our Standard Control... More
Commentary
2018 Formulary Strategy Article
Cost Management
Formulary management is foundational in helping clients control costs. Value-based management strategies build upon the early success of formulary strategy for more targeted,... More
Commentary
Paying for Drugs Based on Outcomes
Cost Management
Value-based management seeks go beyond a static, pre-set price tag to uncover true value for drugs and better health for patients. More
Briefing
Specialty
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature